Global Regulatory Affairs & Dossier Services - CTD / ACTD / eCTD - Regulated and Emerging Markets
In an increasingly complex and volatile global healthcare environment, obtaining swift market authorization demands resilient regulatory strategies and flawless dossier compilation. At PharpleQ Lifesciences, we provide asset-light, comprehensive Regulatory Affairs & Global Dossier Services. We bridge the gap between technical formulation, clinical execution, and commercial launch by translating complex manufacturing and clinical data into audit-proof submissions.Backed by the PharpleQ team's vast experience in international regulatory frameworks, we manage the entire lifecycle of generic, novel pharmaceutical, hybrid, nutraceutical, cosmeceutical, and veterinary product registrations across highly regulated, semi-regulated, and emerging markets.
At PharpleQ, we completely provide support for the dossiers intended for tech-transfer or for the out-licensing of already registered products in regulated or emerging markets.
Global Dossier Formats: CTD vs. eCTD vs. ACTD
Our regulatory documentation team is cross-trained in compiling technical packages across all globally recognized dossier formats, adapting the identical core scientific data to fit specific regional filing requirements.
ICH CTD (Common Technical Document)
- The baseline linear, 5-Module structural layout developed by the International Council for Harmonisation (ICH). Used as the uniform standard for organizing technical information in paper or non-eCTD electronic formats.
eCTD (Electronic Common Technical Document)
- The current mandatory standard for highly regulated markets (US, EU, UK, Canada, Australia, Japan). It utilizes an XML Backbone (eCTD v3.2.2 / v4.0) with dedicated MD5 checksums to guarantee data integrity. It permits dynamic lifecycle tracking (new submissions, replaces, deletes) and features strict internal and external hyperlink cross-referencing.
ACTD (ASEAN Common Technical Document)
- The specialized regional standard adopted by ASEAN member states (e.g., Singapore, Malaysia, Vietnam, Philippines). It condenses the technical data into a 4-Module format, restructuring the documentation to place heavier initial weight on CMC parameters and specific local stability conditions.
Difference in Dossier Modules Across CTD Vs. ACTD Vs. eCTD Formats
To ensure comprehensive tracking, the table below provides a granular analysis of the content required per module, explicitly contrasting how the ICH CTD / eCTD structure differs from the ACTD configuration.
| Module / Part | ICH CTD / eCTD Structural Requirements | ACTD Structural Requirements | Structural & Informational Differences |
|---|---|---|---|
| Module 1 / Part I | Administrative Information & Prescribing Information: Regional application forms, cover letters, labels, cartons, Patient Information Leaflets (PIL), and Summary of Product Characteristics (SmPC). Non-ICH specific. | Administrative Data & Product Information: Application forms, letter of authorization, certification of site GMP status, product labelling text, inserts, and package mock-ups. | Highly region-specific in both. eCTD demands separate XML files for regional administrative headings; ACTD integrates these as linear PDF structures within Part I. |
| Module 2 / Part II | Common Technical Document Summaries: High-level scientific overviews and summaries written by qualified experts covering Quality (QOS), Non-Clinical Overviews, and Clinical Overviews/Summaries. | Quality Document (CMC Summaries & Data): Direct integration of the Quality Overall Summary (QOS) and raw chemistry, manufacturing, and control data under a single section. | Major Difference: ICH CTD splits summaries (M2) from raw data (M3). ACTD merges the quality overview directly with the raw CMC data into Part II, eliminating Module 2 entirely. Non-clinical/clinical summaries move to later sections. |
| Module 3 / Part II | Quality (Chemistry, Manufacturing, & Control): Subdivided into Drug Substance (3.2.S) and Drug Product (3.2.P). Covers characterization, manufacturing process, control of materials, validation data, cleaning limits, and stability data. | Quality Document (Continued): Houses all raw analytical validation, manufacturing process development details, and batch analysis documents within the Part II envelope. | CTD structures Drug Substance and Drug Product into separate alphanumeric nodes (3.2.S and 3.2.P). ACTD organises this data linearly with localized emphasis on Zone IVb stability conditions. |
| Module 4 / Part III | Non-Clinical Study Reports: Full, un-summarized toxicological, pharmacological, and pharmacokinetic laboratory study reports (in-vitro and animal model data). | Non-Clinical Document: Summaries and full studies evaluating pharmacological and toxicological attributes. | CTD structures this tightly via granular sub-folders for distinct toxicity types (acute, sub-chronic, genotoxicity). ACTD presents this data predominantly as high-level literature reviews unless filing a novel entity. |
| Module 5 / Part IV | Clinical Study Reports: Full biopharmaceutic studies (BA/BE study data, 90% confidence interval profiles), human PK/PD reports, and Phase I–IV clinical trial reports. | Clinical Document: Clinical data, human bioequivalence studies, and comprehensive literature validation logs. | eCTD mandates strict leaf referencing of raw clinical datasets (CDISC SDTM/ADaM). ACTD focuses heavily on the final Clinical Study Report (CSR) and bioanalytical verification metrics. |
Product Registration Pathways (Generic, NDA, Hybrid, & 505(b)(2))
PharpleQ architects custom filing matrices adjusted to the regulatory definition of your target molecule, minimizing development budgets while maximizing exclusivity windows.
New Drug Applications (NDA) / Full MAA (US 505(b)(1) / EU Article 8(3))
- Reserved for completely novel chemical or biological entities. Requires the compilation of exhaustive native pre-clinical discovery data (Module 4) and full Phase I–III clinical safety and efficacy trials (Module 5).
Generic Drug Applications (ANDA) (US 505(j) / EU Article 10(1))
- Abbreviated pathways for duplicate formulations of previously authorized reference listed drugs (RLD). Bypasses long-term animal and clinical trials by delivering definitive Module 5 Bioavailability/Bioequivalence (BA/BE) validation data packages.
Hybrid / Hybrid Applications (US 505(b)(2) / EU Article 10(3))
- An advanced strategic corridor for modified iterations of existing molecules (new indications, new dosage forms, changed strengths, or novel combination variants). We leverage historical reference data to bridge safety loops, requiring only target clinical or non-clinical trials to validate the exact modification.
US Patent Certifications: Paragraph III vs. Paragraph IV
When executing generic ANDA filings within the United States, navigating the FDA Orange Book patent landscape requires expert legal-technical timing. PharpleQ handles the documentation workflows for critical patent strategies:
Paragraph I Certification
- Statement that the reference drug has zero patent listings in the Orange Book.
Paragraph II Certification
- Statement that the relevant Orange Book patents have completely expired.
Paragraph III Certification
- A declaration that the sponsor will wait for the explicit expiration date of the listed patent before launching the product commercially. Used to secure Day-1 launch readiness upon patent lapse.
Paragraph IV Certification
A high-stakes assertion that the listed RLD patent is either invalid, unenforceable, or will not be infringed by the generic formulation.
- The 45-Day Clock: Filing a Paragraph IV triggers a mandatory legal notice to the patent holder. If they sue within 45 days, it invokes an automatic 30-month FDA approval stay.
- 180-Day Exclusivity: We help developers target the coveted First-to-File (FTF) status, which rewards successful Paragraph IV challengers with 180 days of absolute generic market exclusivity.
Country & Region-Specific Regulatory Requirements
PharpleQ de-risks global sourcing and simplifies international market navigation by aligning your dossiers with the explicit, complex mandates enforced by regional health authorities.
US (FDA) Market Mandates
- Mandatory eCTD format via the Electronic Submission Gateway (ESG). Strict compliance with 21 CFR Part 11 for data integrity. Requires full CDISC-compliant clinical and non-clinical data models. Stability data must cover a minimum of 6 months of accelerated data and 12 months of long-term data at Zone I/II conditions for initial filing, backed by three pilot or commercial production scale lots.
Europe (EMA) & UK (MHRA) Market Mandates
- Electronic submissions via the Common European Submission Portal (CESP) utilizing centralized (CP), decentralized (DCP), or mutual recognition (MRP) pathways. Dossiers must feature an active Risk Management Plan (RMP) and an environmental risk assessment. Labelling files must remain natively flexible to incorporate multi-language text fields matching European Union target states.
ASEAN & LATAM (ANVISA) Market Mandates
- Acceptance of ACTD (ASEAN) and customized CTD formats (LATAM). Emphasizes native Zone IVb (30°C ± 2°C / 75% ± 5% RH) stability testing data to prove shelf-life under high temperature and humidity profiles. ANVISA mandates strict validation protocols executed locally or explicitly audited by their inspectors, including aggressive mechanical validation parameters for manufacturing sites.
Emerging Markets (CIS, Middle East, Africa)
- Varies between paper CTD folders, semi-electronic formats, and regional portals. Heavily dependent on legalization pathways: requires the preparation of specialized administrative packages including notarized Certificates of Pharmaceutical Product (CPP) matching WHO templates, manufacturing site GMP clear declarations, and apostilled free-sale certifications.
Global Regulatory Timelines & Submission Lifecycles
Understanding health authority review cycles is critical for supply chain planning. We manage your submission roadmap across standard, accelerated, and lifecycle change milestones.
First Submission Lifecycle
Standard Review Timelines
- Full NDA filings typically require 10 to 12 months under US FDA GDUFA/PDUFA mandates or European Centralized Timelines (210 clock days plus stop-clocks). Generic ANDA review matrices average 8 to 10 months assuming clean initial formatting.
Accelerated / Expedited Tracks
- For breakthrough formulations, orphan drugs, or critical shortage assets, we compile packages satisfying US Priority Review or European PRIME / Accelerated Assessment protocols, truncating the authority review window down to 6 months.
Post-Approval Variations Lifecycle
As your commercial processes, equipment scales, or testing facilities evolve, we manage the mandatory post-approval modification packages:
Type IA / CBE-0 (Immediate Change / Notification)
- Minor alterations carrying zero risk to product quality (e.g., tightening an existing specification window or switching to an identical testing tool). Timeline: Immediate execution upon filing.
Type IB / CBE-30 (Changes Being Effected within 30 Days)
- Moderate alterations (e.g., minor adjustments to fluid-bed process controls or expanding batch sizes up to a 10x scale window). Timeline: The health authority has 30 days to raise objections before implementation.
Type II / Prior Approval Supplement (PAS)
- Major process, formulation, raw material source, or structural site changes (e.g., introducing a new Hot-Melt Extrusion or Wurster coating line at a different manufacturing site). Timeline: Requires complete prospective process validation data matrices; review cycles range from 4 to 6 months.
End-to-End Lifecycle Management & Technical Regulatory Dossier Deliverables
Our regulatory operations group does not just compile pages; we build and manage dynamic technical records that safeguard your product’s commercial status from submission to post-approval changes.
- Baseline Compilation & Conversion
- We ingest raw data from your CDMO (manufacturing history, validation runs) and CRO (PK modeling, CSR matrices) and convert it into fully hyperlinked, submission-ready CTD/eCTD/ACTD files.
- Pre-Submission XML Validation
- Every eCTD envelope is processed through qualified electronic validators to guarantee zero broken links, accurate leaf positioning, and validated MD5 checksum verifications prior to submission.
- Dossier Renewal & Annual Maintenance
- Generation of Annual Reports, Periodic Safety Update Reports (PSUR), and timely filing updates to prevent market authorization lapses.